文献速递甲状腺疾病

FcRn抑制剂巴托利单抗治疗甲状腺眼病的概念验证与随机安慰剂对照试验

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

两项研究评估FcRn抑制剂巴托利单抗治疗中重度活动性甲状腺眼病:概念验证试验显示巴托利单抗显著降低致病性抗TSH受体抗体和总IgG(P < .001);随机双盲安慰剂对照试验因血清胆固醇非预期升高而提前终止,实际分析65例(计划77例),12周突眼反应与安慰剂无统计学显著差异,但 orbital muscle volume 在12周下降(P < .03),680 mg组19周生活质量(外观子量表)改善(P < .03)。

要点

  • 巴托利单抗显著降低血清致病性抗TSH受体抗体和总IgG水平(P < .001)。
  • 随机试验因血清胆固醇非预期升高提前终止,12周突眼反应与安慰剂无统计学显著差异。
  • 680 mg组12周眶内肌肉体积下降(P < .03),19周生活质量外观子量表改善(P < .03)。

核心结论

  • 巴托利单抗在甲状腺眼病中显示出降低致病性抗TSH受体抗体和总IgG的效果,并支持其作为潜在疗法的进一步研究。

研究设计与样本

  • 概念验证试验和随机双盲安慰剂对照试验, multicenter 设计,纳入中重度活动性甲状腺眼病患者。
  • 概念验证试验:每周皮下注射巴托利单抗680 mg持续2周,随后340 mg持续4周。
  • 随机双盲试验:按2:2:1:2随机分配至每周巴托利单抗680 mg、340 mg、255 mg或安慰剂,持续12周。
  • 随机试验计划纳入77例,因血清胆固醇非预期升高提前终止,实际分析65例。

主要发现

  • 两项试验均显示巴托利单抗显著降低血清致病性抗TSH受体抗体和总IgG水平(P < .001)。
  • 随机试验中,12周突眼反应巴托利单抗与安慰剂无统计学显著差异,但在多个更早时间点观察到显著差异。
  • 680 mg组12周眶内肌肉体积下降(P < .03),19周生活质量(外观子量表)改善(P < .03)。
  • 巴托利单抗总体耐受性良好,出现白蛋白降低和血脂升高,停药后逆转。

关键数值与推荐

  • 概念验证试验主要结局:血清抗TSH受体抗体和总IgG较基线的变化。
  • 随机试验主要结局:12周突眼反应。
  • 随机试验因血清胆固醇非预期升高终止,实际分析65例(计划77例)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 随机试验因血清胆固醇非预期升高而提前终止,仅分析65例(计划77例)。
  • 12周突眼反应与安慰剂无统计学显著差异。
  • 巴托利单抗治疗中出现白蛋白降低和血脂升高。
  • 作者结论指出结果支持进一步研究,而非当前临床推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED). OBJECTIVE: We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED. DESIGN: Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials. SETTING: Multicenter. PARTICIPANTS: Patients with moderate-to-severe, active TED. INTERVENTION: In the POC trial, patients received weekly subcutaneous injections of batoclimab 680 mg for 2 weeks, followed by 340 mg for 4 weeks. In the double-blind trial, patients were randomized 2:2:1:2 to weekly batoclimab (680 mg, 340 mg, 255 mg) or placebo for 12 weeks. MAIN OUTCOME: Change from baseline in serum anti-TSH-R-Ab and total IgG (POC); 12-week proptosis response (randomized trial). RESULTS: The randomized trial was terminated because of an unanticipated increase in serum cholesterol; therefore, data from 65 of the planned 77 patients were analyzed. Both trials showed marked decreases in pathogenic anti-TSH-R-Ab and total IgG serum levels (P < .001) with batoclimab. In the randomized trial, there was no statistically significant difference with batoclimab vs placebo in proptosis response at 12 weeks, although significant differences were observed at several earlier timepoints. In addition, orbital muscle volume decreased (P < .03) at 12 weeks, whereas quality of life (appearance subscale) improved (P < .03) at 19 weeks in the 680-mg group. Batoclimab was generally well tolerated, with albumin reductions and increases in lipids that reversed upon discontinuation. CONCLUSIONS: These results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023. PMID: 37390454. doi:10.1210/clinem/dgad381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。